Unravelling glioblastoma’s secrets and harnessing two decades of progress, page-5

GBM AGILE also assesses paxalisib in recurrent GBM.
There is no prior data on paxalisib in this sub-population.

I also take it as a good sign that the results for paxalisib have not been published.
Paxalisib was arguably easier to administer as an oral than an iv drug like VAL-083 - meaning that patient recruitment should have been faster.
But VAL-083 was also assessed in methylated patients.

A big question for me the split between newly-diagnosed vs recurrent cases in the paxalisib arm.

John Friend confirmed in the latest IR video that GBM AGILE results for paxalisib are still on track for publication in 2023.